CytoDyn Inc (CYDY) Stock Reaches Towards New Low: What’s The Buzz?

A look at some of the latest developments with regards to the company might provide a better idea. Yesterday, the company announced that some of its highest ranking executives included Nader Pourhassan, the President and Chief Executive Officer, are all set to host a webcast for the investment community on June 21, 2021.

665
Microscopic illustration of the spreading 2019 corona virus that was discovered in Wuhan, China. The image is an artisic but scientific interpretation, with all relevant surface details of this particular virus in place, including Spike Glycoproteins, Hemagglutinin-esterase, E- and M-Proteins and Envelope.

In recent times, CytoDyn Inc (OTCMKTS:CYDY) has not had a particularly great time in the markets and that has been reflected in its share pice as well. Over the course of the past week, the stock has tanked by as much as 14% and it is a situation in which, it is probably important for investors to figure out if this might be an opportunity to get into the CytoDyn stock.

A look at some of the latest developments with regards to the company might provide a better idea. Yesterday, the company announced that some of its highest-ranking executives included Nader Pourhassan, the President and Chief Executive Officer, are all set to host a webcast for the investment community on June 21, 2021.

At this particular webcast, the company’s management is going to have a discussion on the data from the long hauler’s COVID 19 trial. In addition to that, the management will also provide updates with regards to the COVID 19 trials that are going on in other countries. The company has come into prominence in recent times due to its product leronlimab, which has been presented as a potential cure for COVID 19 infection.

Earlier on this month, the company had announced that the Philippines company Chiral Pharma Corporation had placed the first purchase order for CytoDyn’s leronlimab.

The order had been placed by Chiral Pharma under the provisions of the Compassionate Special Permit which is meant for treating critically ill COVID 19 patients in the Philippines. It was also announced that once the order is fulfilled, the revenues in relation to this order are going to be realized by CytoDyn. It goes without saying that it is a major development for the company and it is going to be interesting to watch if CytoDyn manages to garner more orders in the coming months.